Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Urinary Renin in Patients and Mice With Diabetic Kidney Disease.

Tang J, Wysocki J, Ye M, Vallés PG, Rein J, Shirazi M, Bader M, Gomez RA, Sequeira-Lopez MS, Afkarian M, Batlle D.

Hypertension. 2019 Jul;74(1):83-94. doi: 10.1161/HYPERTENSIONAHA.119.12873. Epub 2019 May 13.

PMID:
31079532
2.

Apelinergic system in the kidney: implications for diabetic kidney disease.

Müller T, Kalea AZ, Marquez A, Hsieh I, Haque S, Ye M, Wysocki J, Bader M, Batlle D.

Physiol Rep. 2018 Dec;6(23):e13939. doi: 10.14814/phy2.13939.

3.

Hyperkalemic Forms of Renal Tubular Acidosis: Clinical and Pathophysiological Aspects.

Batlle D, Arruda J.

Adv Chronic Kidney Dis. 2018 Jul;25(4):321-333. doi: 10.1053/j.ackd.2018.05.004. Review.

PMID:
30139459
4.

Hypokalemic Distal Renal Tubular Acidosis.

Vallés PG, Batlle D.

Adv Chronic Kidney Dis. 2018 Jul;25(4):303-320. doi: 10.1053/j.ackd.2018.05.003. Review.

PMID:
30139458
5.

Renal Tubular Acidosis and the Nephrology Teaching Paradigm.

Batlle D, Arruda J.

Adv Chronic Kidney Dis. 2018 Jul;25(4):301-302. doi: 10.1053/j.ackd.2018.05.002. No abstract available.

PMID:
30139457
6.

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation.

Liu P, Wysocki J, Souma T, Ye M, Ramirez V, Zhou B, Wilsbacher LD, Quaggin SE, Batlle D, Jin J.

Kidney Int. 2018 Jul;94(1):114-125. doi: 10.1016/j.kint.2018.01.029. Epub 2018 Apr 22.

PMID:
29691064
7.

The Urine Anion Gap in Context.

Batlle D, Ba Aqeel SH, Marquez A.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):195-197. doi: 10.2215/CJN.13791217. Epub 2018 Jan 8. No abstract available.

8.

Angiotensinogen as a biomarker of acute kidney injury.

Ba Aqeel SH, Sanchez A, Batlle D.

Clin Kidney J. 2017 Dec;10(6):759-768. doi: 10.1093/ckj/sfx087. Epub 2017 Jul 28. Review.

9.

Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap.

Batlle D, Chin-Theodorou J, Tucker BM.

Am J Kidney Dis. 2017 Sep;70(3):440-444. doi: 10.1053/j.ajkd.2017.04.017. Epub 2017 Jun 7.

10.

Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.

Wysocki J, Goodling A, Burgaya M, Whitlock K, Ruzinski J, Batlle D, Afkarian M.

Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F487-F494. doi: 10.1152/ajprenal.00074.2017. Epub 2017 May 3.

11.

A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13.

Liu P, Wysocki J, Serfozo P, Ye M, Souma T, Batlle D, Jin J.

Sci Rep. 2017 Apr 5;7:45473. doi: 10.1038/srep45473.

12.

Hypertension and Its Complications in a Young Man With Autoimmune Disease.

Miller-Hodges E, Dominiczak AF, Jennings GL, Oparil S, Batlle DC, Elijovich F, Basile JN, Laffer CL, Oliveras A, Dhaun N.

Hypertension. 2017 Apr;69(4):536-544. doi: 10.1161/HYPERTENSIONAHA.117.09036. Epub 2017 Feb 27. No abstract available.

PMID:
28242716
13.

Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II.

Maier C, Schadock I, Haber PK, Wysocki J, Ye M, Kanwar Y, Flask CA, Yu X, Hoit BD, Adams GN, Schmaier AH, Bader M, Batlle D.

J Mol Med (Berl). 2017 May;95(5):473-486. doi: 10.1007/s00109-017-1513-9. Epub 2017 Feb 3.

PMID:
28160049
14.

Hypokalemia associated with acute colonic pseudo-obstruction in an ESRD patient.

Boobés K, Rosa RM, Batlle D.

Clin Nephrol. 2017 Mar;87 (2017)(3):152-156. doi: 10.5414/CN109002.

PMID:
28025959
15.

Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Wysocki J, Ye M, Khattab AM, Fogo A, Martin A, David NV, Kanwar Y, Osborn M, Batlle D.

Kidney Int. 2017 Jun;91(6):1336-1346. doi: 10.1016/j.kint.2016.09.032. Epub 2016 Dec 4.

16.

Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?

Wysocki J, Batlle D.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1515-7. doi: 10.2215/CJN.07780716. Epub 2016 Aug 18. No abstract available.

17.

The Colon as the Potassium Target: Entering the Colonic Age of Hyperkalemia Treatment?

Batlle D, Boobés K, Manjee KG.

EBioMedicine. 2015 Oct 29;2(11):1562-3. doi: 10.1016/j.ebiom.2015.10.027. eCollection 2015 Nov. No abstract available.

18.

Snapshot Hemodynamics and Clinical Outcomes in Hypertension: Precision in the Measurements Is Key.

Pandit JA, Batlle D.

Hypertension. 2016 Feb;67(2):270-1. doi: 10.1161/HYPERTENSIONAHA.115.06818. Epub 2015 Dec 22. Review. No abstract available.

PMID:
26693819
19.

Angiotensins and the heart: is angiotensin-(1-7) cardioprotective?

Wysocki J, Wilsbacher L, Batlle D.

Hypertension. 2015 Aug;66(2):260-2. doi: 10.1161/HYPERTENSIONAHA.115.05093. Epub 2015 Jun 15. No abstract available.

20.

Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.

Wysocki J, Ye M, Batlle D.

Am J Hypertens. 2015 Dec;28(12):1418-26. doi: 10.1093/ajh/hpv054. Epub 2015 May 11.

21.

Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium.

Hsu CY, Ballard S, Batlle D, Bonventre JV, Böttinger EP, Feldman HI, Klein JB, Coresh J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar SS, Whitehead KM, Nelson RG; CKD Biomarkers Consortium.

Clin J Am Soc Nephrol. 2015 May 7;10(5):894-902. doi: 10.2215/CJN.11541114. Epub 2015 Mar 4. Review.

22.

ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney.

Wysocki J, Ortiz-Melo DI, Mattocks NK, Xu K, Prescott J, Evora K, Ye M, Sparks MA, Haque SK, Batlle D, Gurley SB.

Physiol Rep. 2014 Mar 24;2(3):e00264. doi: 10.1002/phy2.264. Print 2014.

23.

Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.

Chou JC, Rollins SD, Ye M, Batlle D, Fawzi AA.

Invest Ophthalmol Vis Sci. 2014 Apr 17;55(4):2516-25. doi: 10.1167/iovs.13-13676.

24.

Improving CKD therapies and care: a National Dialogue.

Kaskel F, Batlle D, Beddhu S, Daugirdas J, Feldman H, Ferris M, Fine L, Freedman BI, Kimmel PL, Flessner MF, Star RA; Kidney Research National Dialogue (KRND).

Clin J Am Soc Nephrol. 2014 Apr;9(4):815-7. doi: 10.2215/CJN.12631213. Epub 2014 Feb 7.

25.

Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro.

Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D.

Hypertension. 2014 Apr;63(4):774-82. doi: 10.1161/HYPERTENSIONAHA.113.02856. Epub 2014 Jan 20.

26.

Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse.

Riera M, Márquez E, Clotet S, Gimeno J, Roca-Ho H, Lloreta J, Juanpere N, Batlle D, Pascual J, Soler MJ.

PLoS One. 2014 Jan 6;9(1):e84683. doi: 10.1371/journal.pone.0084683. eCollection 2014. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/2a7b69d2-a049-448e-b584-51e4c1e8a50d.

27.

TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation.

Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M.

J Pathol. 2013 Dec;231(4):480-94. doi: 10.1002/path.4250.

PMID:
24037740
28.

ACE2 alterations in kidney disease.

Soler MJ, Wysocki J, Batlle D.

Nephrol Dial Transplant. 2013 Nov;28(11):2687-97. doi: 10.1093/ndt/gft320. Epub 2013 Aug 16. Review.

29.

Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?

Wysocki J, Batlle D.

Nephrol Dial Transplant. 2013 Sep;28(9):2200-2. doi: 10.1093/ndt/gft240. Epub 2013 Jun 19. No abstract available.

30.

Regulation of urinary ACE2 in diabetic mice.

Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Batlle D.

Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F600-11. doi: 10.1152/ajprenal.00600.2012. Epub 2013 Jun 12.

31.

Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.

Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM.

Am J Hypertens. 2013 May;26(5):583-90. doi: 10.1093/ajh/hps090. Epub 2013 Mar 4.

32.

Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.

Haque SK, Ariceta G, Batlle D.

Nephrol Dial Transplant. 2012 Dec;27(12):4273-87. doi: 10.1093/ndt/gfs493. Review.

33.

Genetic causes and mechanisms of distal renal tubular acidosis.

Batlle D, Haque SK.

Nephrol Dial Transplant. 2012 Oct;27(10):3691-704. doi: 10.1093/ndt/gfs442. Review.

PMID:
23114896
34.

Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, Poglitsch M, Schuster M, Batlle D.

Hypertension. 2012 Sep;60(3):730-40. doi: 10.1161/HYPERTENSIONAHA.112.198622. Epub 2012 Jul 9.

35.

Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice.

Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD.

Kidney Int. 2012 Aug;82(3):292-303. doi: 10.1038/ki.2012.83. Epub 2012 Apr 4.

36.

New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy.

Soler MJ, Riera M, Batlle D.

Exp Diabetes Res. 2012;2012:616313. doi: 10.1155/2012/616313. Epub 2012 Feb 8. Review.

37.

Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.

Batlle D, Wysocki J, Soler MJ, Ranganath K.

Kidney Int. 2012 Mar;81(6):520-8. doi: 10.1038/ki.2011.381. Epub 2011 Nov 23. Review.

38.

Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study.

Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Troca JJ, Natarajan A, Batlle D.

BMC Nephrol. 2011 Oct 5;12:53. doi: 10.1186/1471-2369-12-53.

39.

ACE2 and diabetes: ACE of ACEs?

Batlle D, Jose Soler M, Ye M.

Diabetes. 2010 Dec;59(12):2994-6. doi: 10.2337/db10-1205. No abstract available.

40.

Potential benefits of alkali therapy to prevent GFR loss: time for a palatable 'solution' for the management of CKD.

Sahni V, Rosa RM, Batlle D.

Kidney Int. 2010 Dec;78(11):1065-7. doi: 10.1038/ki.2010.364.

41.

Vascular angiotensin-converting enzyme 2: lord of the ring?

Batlle D, Wysocki J, Khan MS.

Circ Res. 2010 Oct 1;107(7):822-4. doi: 10.1161/CIRCRESAHA.110.229831. No abstract available.

42.

Evaluation of renal hypoxia in diabetic mice by BOLD MRI.

Prasad P, Li LP, Halter S, Cabray J, Ye M, Batlle D.

Invest Radiol. 2010 Dec;45(12):819-22. doi: 10.1097/RLI.0b013e3181ec9b02.

43.

Acute renal failure and severe hypertension from a page kidney post-transplant biopsy.

Posadas MA, Yang V, Ho B, Omer M, Batlle D.

ScientificWorldJournal. 2010 Aug 3;10:1539-42. doi: 10.1100/tsw.2010.150.

44.

Apelin and ACE2 in cardiovascular disease.

Kalea AZ, Batlle D.

Curr Opin Investig Drugs. 2010 Mar;11(3):273-82. Review.

PMID:
20178040
45.

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D.

Hypertension. 2010 Jan;55(1):90-8. doi: 10.1161/HYPERTENSIONAHA.109.138420. Epub 2009 Nov 30.

46.

Low mortality and key aspects of delivery of care for end-stage renal disease in Italy.

Lauder A, Schieppati A, Conte F, Remuzzi G, Batlle D.

ScientificWorldJournal. 2009 May 21;9:349-59. doi: 10.1100/tsw.2009.43.

47.

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.

Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D.

Am J Physiol Renal Physiol. 2009 Feb;296(2):F398-405. doi: 10.1152/ajprenal.90488.2008. Epub 2008 Nov 12.

48.

Acute renal failure from adulteration of milk with melamine.

Yang VL, Batlle D.

ScientificWorldJournal. 2008 Oct 9;8:974-5. doi: 10.1100/tsw.2008.137.

49.

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.

Wang X, Harris PC, Somlo S, Batlle D, Torres VE.

Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527. Epub 2008 Sep 30.

50.

Pharmacologic modulation of ACE2 expression.

Soler MJ, Barrios C, Oliva R, Batlle D.

Curr Hypertens Rep. 2008 Oct;10(5):410-4. Review.

PMID:
18775121

Supplemental Content

Loading ...
Support Center